1. Hepatitis B serological markers and plasma DNA concentrations
- Author
-
Price, Huw, Dunn, David, Zachary, Tamale, Vudriko, Tobias, Chirara, Michael, Kityo, Cissy, Munderi, Paula, Spyer, Moira, Hakim, James, Gilks, Charles, Kaleebu, Pontiano, Pillay, Deenan, Gilson, Richard, and DART Virology Group
- Subjects
virus diseases ,digestive system diseases - Abstract
OBJECTIVES: To examine hepatitis B (HBV) serological markers and plasma DNA concentrations in a large group of untreated HBV/HIV-coinfected individuals in two sub-Saharan settings. DESIGN: Baseline analysis of a randomized controlled trial. METHODS: DART was a large trial of treatment monitoring practices in HIV-infected adults with advanced disease starting antiretroviral therapy at centres in Kampala or Entebbe, Uganda (n = 2317) and Harare, Zimbabwe (n = 999). HBV serological markers [antibody to HBV core antigen, HBV surface antigen (HBsAg), antibody to HBV surface antigen, HBV 'e' antigen (HBeAg), and antibody to hepatitis B 'e' antigen] and plasma HBV DNA viral load were measured retrospectively on stored baseline samples. Logistic regression was used to examine associations with baseline demographic and clinical factors. RESULTS: The rate of HBsAg positivity was significantly higher in Zimbabwe than Uganda (12.2 vs. 7.7%, adjusted odds ratio = 1.54, P
- Published
- 2017